BioCentury
ARTICLE | Clinical News

BNC210: Phase II data

September 26, 2016 7:00 AM UTC

Top-line data from the double-blind, placebo- and lorazepam-controlled, 4-way crossover, U.K. Phase II BNC210.006 trial in 24 patients with untreated GAD showed that a single oral dose of 300 mg BNC21...